December 6, 2022

Volume XII, Number 340

Advertisement

December 05, 2022

Subscribe to Latest Legal News and Analysis

EUON Publishes Nanopinion on the Transportation of Nanoparticles across the Blood-Brain Barrier

On September 13, 2022, the European Union (EU) Observatory for Nanomaterials (EUON) published a Nanopinion entitled “Can the Brain’s Gatekeeper Fight a Nano-Attack?” by Dr. Eugenia (Éva) Valsami-Jones, Professor of Environmental Nanoscience at the University of Birmingham, who co-authored an article entitled “Biotransformation modulates the penetration of metallic nanomaterials across an artificial blood–brain barrier model.” The researchers set out to explore systematically how different nanoparticle properties play a role in their potential to be transported across the blood-brain barrier (BBB). To be able to test their hypotheses, they constructed a model BBB inside a special permeable well, on which human cells representative of the BBB were cultured and tested to ensure their function precisely replicated that of the real barrier. The researchers then investigated what factors affect the ability of a number of model nanoparticles, specifically cerium oxide, iron oxide, zinc oxide, and silver in different particle sizes and shapes, to cross the model BBB. Valsami-Jones states that the researchers discovered that silver and zinc oxide nanoparticles, “which are often used in consumer goods, including healthcare products, have the potential to cross the BBB and enter the brain in the form of both particles and dissolved ions, depending on the size, shape and exposure concentration.” These nanoparticles can also affect cellular function and integrity of the BBB. The study revealed how nanoparticles may gain access to the brain and how they might bypass the brain’s guardian BBB. According to Valsami-Jones, “[t]he knowledge acquired can help make the use of nanoparticles safer, by ensuring, for example, that properties that facilitate crossing of the BBB are designed out of products that could come to direct contact with our bodies. In contrast, if nanoparticles are used as vehicles for drug delivery, for example in order to fight diseases such as Parkinson’s and Alzheimer’s, then we should design in the properties that give them easy passage through the BBB.”

©2022 Bergeson & Campbell, P.C.National Law Review, Volume XII, Number 257
Advertisement
Advertisement
Advertisement

About this Author

Lynn Bergeson, Campbell PC, Toxic Substances Control Act Attorney, federal insecticide lawyer, industrial biotechnology legal counsel, Food Drug Administration law
Managing Partner

Lynn L. Bergeson has earned an international reputation for her deep and expansive understanding of the Toxic Substances Control Act (TSCA), the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), European Union Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), and especially how these regulatory programs pertain to nanotechnology, industrial biotechnology, synthetic biology, and other emerging transformative technologies. Her knowledge of and involvement in the policy process allows her to develop client-focused strategies whether...

202-557-3801
Carla Hutto, Bergeson Campbell PC environmental law regulatory analyst,Toxic Substances Control Act law attorney
Regulatory Analyst

Since 1996, Carla Hutton has monitored, researched, and written about regulatory and legislative issues that may potentially affect Bergeson & Campbell, P.C. (B&C®) clients. She is responsible for creating a number of monthly and quarterly regulatory updates for B&C's clients, as well as other documents, such as chemical-specific global assessments of regulatory developments and trends. She authors memoranda for B&C clients on regulatory and legislative developments, providing information that is focused, timely and applicable to client...

202-557-3809
Advertisement
Advertisement
Advertisement